Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Medical Officer | March 09, 2022 | March 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date March 09, 2022 · Filed March 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2032-03-09 | Direct | 370,016 |
Reported balance
After 2022-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-09 · Grant · Acquired 170,016 · Balance 370,016 F1: 42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2022 Filed Mar 10, 2022 18:42 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 170,016 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005795 · wf-form4_164695574769782.xml · derivative · entry 1 Ruffner Katherine L · CIK 0001872306 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,016 Underlying: Common Stock · 170,016 shares Expires 2032-03-09 F1 · derivative.exercise_date: 42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:00 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001628280-21-013826 · wf-form4_162629281654783.xml · derivative · entry 1 Ruffner Katherine L · CIK 0001872306 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-07-12 F1 · derivative.exercise_date: 25% vest on 7/12/2022. The remainder vest in equal installments monthly for 36 months beginning on 8/12/2022 through 7/12/2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.